Clinical Trials Logo

Sepsis clinical trials

View clinical trials related to Sepsis.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT04636554 No longer available - Covid19 Clinical Trials

Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia

Start date: n/a
Phase:
Study type: Expanded Access

Phage Treatment in Covid-19 Patients with Bacterial Co-Infections

NCT ID: NCT04597242 No longer available - Covid19 Clinical Trials

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

Start date: n/a
Phase:
Study type: Expanded Access

This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI), including right-sided endocarditis (R-IE), who are hospitalized with coronavirus disease 2019 (COVID-19). Patients with left-sided endocarditis (L-IE) are excluded. Patients will receive a single dose of exebacase. Patients will continue to receive antistaphylococcal antibiotics as prescribed by the treating physician. Exebacase Phase 3 study sites (Study CF-301-105) may participate in this Expanded Access study (Study CF-301-107). Exebacase, a direct lytic agent, is an entirely new treatment modality against S. aureus. Exebacase is a recombinantly-produced, purified cell wall hydrolase enzyme that results in rapid bacteriolysis, potent biofilm eradication, synergy with antibiotics, low propensity for resistance, and the potential to suppress antibiotic resistance when used together with antibiotics. Exebacase represents a first-in-field, first-in-class treatment with the potential to improve clinical outcome when used in addition to standard-of-care antibiotics to treat S. aureus BSI including IE.

NCT ID: NCT04352985 No longer available - Septic Shock Clinical Trials

Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

Start date: n/a
Phase:
Study type: Expanded Access

Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock